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ABSTRACT 
 
Activated CD4+ T-cells targeting specific auto-antigenic peptides of myelin sheath 
proteins are thought to mediate the pathogenesis of myelin degeneration, axonal and neuronal 
damage, and glial scaring in multiple sclerosis (MS) patients and experimental autoimmune 
encephalomyelitis (EAE) mouse models.  The disease mechanisms that cause MS remain 
unknown, but susceptibility maps to specific HLA-DRβ1 alleles (especially 04.01, and 15.01) 
whose products help present antigens to the immune system.  To investigate the genetic 
predisposition of MS in patients as it pertains to specific peptide/MHC complexes, three 
recombinant HLA-DRβ1 complexes (01.01 (control), 04.01, and 15.01) were constructed 
containing 18 different peptides derived from three sheath proteins: myelin proteolipid protein 
(PLP), myelin oligodendrocyte glycoprotein (MOG), and myelin basic protein (MBP).  The 
genes were cloned into the pBAC vector and transfected into SF9 insect cells to evaluate surface 
expression as it relates to the auto-antigenic activity of various peptide/MHC combinations.  
FACS analysis was used to evaluate HLA-DR expression in the transfected SF9 cells. Individual 
myelin peptides were also assayed for the ability to induce EAE in transgenic HLA-DRβ1 04.01 
and 15.01 mice.  The data showed that two specific sheath peptides (MBP-30-44 and MOG-25-
55) induced MS-like paralysis when injected into HLA-DRβ1-15.01 mice, indicating those 
peptide/HLA-15.01 combinations could play a role in MS induction.  Ultimately, the 
peptide/HLA-DR constructs corresponding to encephalogenic epitopes will be used to make 
pMHC tetramers to monitor the myelin-specific T cell response in MS patients. 
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BACKGROUND 
 
 
Autoimmune Disorders   
Autoimmune disorders are a systemic failure of the body’s immune system to recognize 
antigens of healthy cells and tissues as self (non-foreign). Immune cells normally removed from 
the body that recognize self-antigens are not eliminated and generate a progressive deterioration 
of healthy tissue which often leads to debilitating circumstances that range from mild to death. 
Over 80 different autoimmune disorders have been characterized, and many more diseases are 
believed to be autoimmune driven. Some of the best known autoimmune diseases are rheumatoid 
arthritis, vitiligo, psoriasis, type-1 diabetes, and multiple sclerosis. Auto-immune responses are 
usually thought to be spontaneous or genetically predisposed lymphocyte attacks that occur on 
specific antigens at the surface of healthy cells and tissues. The differences among the various 
diseases lie in which peptide becomes auto-antigenic and the type of the immune responses.  
This project investigated the autoimmune disorder multiple sclerosis. 
 
Multiple Sclerosis 
Multiple sclerosis (MS) is the most common autoimmune disorder of the central nervous 
system (Berer and Krishnamoorthy, 2014).  Between 2 and 2.5 million people are thought to be 
affected globally, with rates varying widely among different populations (Global Burden of 
Disease Study, 2013).  It is an inflammatory disease in which the myelin sheath insulating covers 
of nerve cells in the brain and spinal cord become damaged.  The myelin sheath is a multi-
layered membrane, unique to the nervous system, which functions as an insulator to greatly 
increase the velocity of axonal impulse conduction.  Damage to the sheath disrupts nervous 
system communication, resulting in a wide range of symptoms including physical and mental 
(Compston and Coles, 2008).  There is no known cure.  MS has several forms. Symptoms can 
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either occur in isolated attacks (relapsing MS), or increase over time (progressive MS) (Lublin 
and Reingold, 1996).  Permanent neurological problems often occur as the disease advances.  
Symptoms of the disease differ between individuals making a definitive diagnosis 
difficult without an MRI. The most common symptoms are fatigue, numbness, tingling, 
weakness, dizziness, vertigo, spasticity (wide-range of muscle spasms), vision problems, bladder 
problems, bowel problems, emotional changes, depression, body pain, and sexual problems 
(National Multiple Sclerosis Society).  Lesser common MS symptoms include speech problems, 
tremors, breathing problems, headaches, seizures, itching, hearing loss, and swallowing problems 
(National Multiple Sclerosis Society).  Leaving primary symptoms untreated can cause 
debilitating secondary and tertiary symptoms such as constant urinary tract infections, decreased 
bone density, shallow breathing, and immobility (National Multiple Sclerosis Society).   
 
MS Pathophysiology 
MS has three main characteristics: 1) the formation of lesions in the central nervous 
system (also called plaques), 2) inflammation, and 3) the destruction of the myelin sheaths of 
neurons (Compston and Coles, 2008).  The name multiple sclerosis refers to the plaques or lesions 
(sclerae) that form in the nervous system. The lesions most commonly form in the white matter 
in the optic nerve, brain stem, basal ganglia, and spinal cord, or white matter tracts close to the 
lateral ventricles (Compston and Coles, 2008).  White matter cells carry signals between grey 
matter areas (where neuronal processing is done) and the rest of the body. The peripheral 
nervous system is rarely involved.  MS involves the loss of oligodendrocytes, the cells 
responsible for creating and maintaining the myelin sheath fatty layer that helps the neurons 
carry electrical signals.  The loss of oligodendrocytes results in a thinning of myelin and, as the 
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disease advances, the breakdown of neuronal axons. Scars eventually result from an ineffective 
repair process (Chari, 2007).   
With respect to the inflammation and destruction of the myelin sheath, the inflammatory 
process is caused by CD4+ T-cells that gain entry into the brain via disruptions in the blood–
brain barrier (BBB). The T-cells recognize myelin as foreign and attack it.  As the attack 
progresses, the BBB breaks down further, causing other damaging effects such as swelling, 
activation of macrophages, and more activation of cytokines and other destructive proteins.  MS 
has a complex and poorly understood pathogenesis (McFarland and Martin, 2007). The disease is 
a degenerative process which begins with the formation of acute inflammatory legions at the 
blood-brain barrier (BBB).  This leads to demyelination, axonal and neuronal damage, and glial 
scaring (McFarland and Martin, 2007). The current model suggests that the breakdown of the 
BBB is caused by an active T-cell immune response to the central nervous system (CNS). The 
specific target antigen(s) in multiple sclerosis are not well characterized, but several studies have 
suggested that the T-cell response targets myelin antigens (McFarland and Martin, 2007), 
although no specific myelin antigens have been proven to participate in the disease. 
 
MS Genetics and HLA 
MS is believed to develop from the interaction of the individual's genetics and as yet 
unidentified environmental causes.  MS is not considered a hereditary disease, but several 
genetic variations have been shown to increase risk (Dymet et al., 2004).  In identical twins, both 
individuals are affected about 30% of the time, while only 5% are affected for non-identical 
twins (Hassan-Smith and Douglas, 2011).  If both parents are affected, the risk in their children 
is 10 times that of the general population (Milo and Kahana, 2010). 
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Genes linked with MS predisposition mostly include mutations in the human leukocyte 
antigen (HLA) system.  This system is a group of genes located on chromosome-6 (Figure-1) 
that serves as the major histocompatibility complex (MHC).  Mutations in the HLA region 
correlating with MS have been known for over 30 years, and the same region has also been 
implicated in the development of other autoimmune diseases such as diabetes type I and systemic 
lupus erythematosus (Baranzini, 2011).  The strongest correlations between MS and genes occur 
at the HLA-DRβ1 locus with alleles HLA-DRB1 15.01 and HLA-DQ6 (diagram left side) 
(Barcellos, 2006; Deluca et al., 2007; Compston and Coles, 2008; Comebella et al, 2008).  It has 
been estimated that HLA mutations account for 20-60% of MS genetic predispositions 
(Baranzini, 2011; Briggs et al, 2010).  
Other than the HLA locus, modern genetic methods (genome-wide association studies) 
have discovered at least twelve other genes that modestly increase the probability of MS 
(Baranzini, 2011).  Other loci have been shown to have a protective effect, such as HLA-C554 and 
HLA-DRB1*11.  A genome-wide scan of 500,000 single nucleotide polymorphisms (SNPs) 
identified locus 13q31.3 as being associated with MS (Comabella et al., 2008). 
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Figure-1:  Diagram of Human Chromosome-6 Showing Genes 
Associated with Multiple Sclerosis.  Shown are the genes of the human 
leukocyte antigen (HLA) system (diagram left side) which serve as a 
major histocompatibility complex.  Strong associations are known for 
HLA-DR15 and HLA-DQ6.  (Compston and Coles, 2008) 
 
This MQP will examine HLA-DRβ1variants 15.01 and 04.01, both have been correlated 
with MS patients (Weatherby et al., 2001). HLA-β1 variant 15.01 is found more frequently in 
MS patients and is associated with an early development of MS symptoms and a worsening of 
symptoms at a later stage (15 years or more) (Weatherby et al., 2001). The heterogeneous 
presentation of MS in patients suggests that there are multiple antigen/peptide and HLA 
combinations associated with the pathogenesis of the disease (Disanto et al., 2011). The HLA-
DR locus is downstream of the HLA-DQ locus and upstream the class III and class I HLA loci 
(Figure-2).  The HLA-DR gene contains two β loci and one α locus. HLA-DRα has no known 
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functional variation and only encodes 3 alleles, unlike the HLA-DRβ loci (Janeway et al., 2008). 
The two HLA-DRβ1 loci in particular are ubiquitous and encode an estimated 463 alleles which 
allows it to comprise the majority of variation in the HLA-DR gene segment (Janeway et al., 
2008). Most of the variation occurs in the HLA-DRβ1 peptide-binding groove, enabling the 
complex to bind with a wide variety of peptides (9 amino acids or longer) and T-cell receptors 
(Janeway et al., 2008).  
 
 
 
 
 
Figure-2: Diagram of the Genetic Organization of the Human Leukocyte Antigen 
(HLA) Locus. The figure shows three classes of HLA genes: class II (left), class III 
(middle), and class I (right). Most of the known MS variants map to the HLA-DRβ1 
locus (yellow, diagram center). The HLA-DP, HLA-DOA, HLA-DOB, and the HLA-DQ 
regions (and their corresponding molecules LMP, TAP, and TAPBP) are shown upstream 
of the HLA-DR regions. (Janeway et al., 2008) 
 
Other Factors Correlating with MS 
Environmental factors like vitamin D deficiency from lack of sunlight (Hansdottir et al., 
2008; Pereira et al., 2015), viral infections such as Epstein-Barr virus (Ascherio and Munger, 2007; 
Serafini et al., 2007; Pereira et al., 2015), and smoking (Ramagoplan et al., 2013; Pereira et al., 
2015) have also been shown to increase the risk of developing MS, although the mechanisms 
remain unknown.  
 
EAE Mouse Model 
To study the pathogenic mechanisms of MS, an experimental autoimmune 
encephalomyelitis (EAE) animal model is often used. This model uses the artificial induction of 
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activated T-cells to cause inflammation, demyelination, axonal loss, and gliosis (Constantinescu 
et al., 2011) which mimics MS.  The model is often used in MS research because of its versatility 
of induction, and the ability of EAE to accurately mimic MS pathogenesis (Constantinescu et al., 
2011).  
EAE induction usually uses adjuvants to sensitize the animal’s immune system to myelin 
antigens. The adjuvants commonly contain bacterial components that produce a strong immune 
reaction, and as a result compel auto-reactive T-cells to the BBB (Constantinescu et al., 2011). 
Lethal irradiation is sometimes used to activate EAE because it disrupts the BBB artificially 
allowing activated myelin T-cells to more easily access the myelin proteins. The artificial 
induction process is unlike the induction of MS, but the model continues to be used to test MS 
drugs and study the disease.  Due to the use of an artificial induction system for inducing EAE, 
the mouse model is not used for studying MS genetic predispositions.  The EAE model only 
provides researches with a blueprint for creating treatments that can inhibit the immune system 
and/or inhibit the migration of CD4+ T-cells to the BBB.  
 
T-Cell Development 
Because MS is driven by myelin-activated CD4+ T-cells that infiltrate the BBB, this 
MQP project will focus on the CD4+ T-cell activation response in MS, and the formation of 
CD4+ T-cells is discussed here.  T-cell development is heavily driven by the thymic 
microenvironment and the binding of the cells to peptide-major histocompatibility complex’s 
(MHCs) at the surface of antigen presenting cells (APCs) (Figure-3). T-cell fate begins when 
lymphoid progenitors derived from hematopoietic stem cells migrate from the bone marrow to 
the thymus; simultaneously losing their potential for becoming natural killer cells and B-cells 
(Germain, 2002). T-cell-committed lymphoid progenitors in the thymus lack a T-cell receptor 
(TCR), and are also CD4 and CD8 negative, so are termed double-negative (DN) T-cells (i.e. 
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TCR-negative and CD4-negative) (Germain, 2002). DN T-cells can then differentiate into either 
γδ or αβ TCR-expressing cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3: Diagram Outlining T-Cell Development in the Thymus. Shown are the 
processes of positive selection (whereby CD8+ and CD4+ T-cells are made) (diagram 
center) and negative selection (diagram lower left) whereby T-cells are destroyed.  
(Germain, 2002) 
 
Formation of αβ TCR-Expressing CD4+ T-Cells 
This project focuses on the αβ TCR-expressing cells which give rise to CD4+ T-cells. 
DN T-cells first begin to express the pre-TCR-α chain encoded by a non-rearranging locus. The 
TCR-β chain unlike the TCR-α chain is produced through somatic recombination which creates 
enormous sequence variability within a structurally conserved framework (Germain, 2002). The 
TCR-β locus consists of three complementarity determining regions (CDRs) CDR1, CDR2, and 
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CDR3, respectively. The CDR3 region of the TCR-β locus is the most structurally variable 
region of the locus, containing V, D, and J segments which produce highly specific CDRs 
referred to as a V(D)J recombination (Harraway, 2013 ). The pre-αβ TCR rearrangement creates 
approximately 1x1015 unique T-cell receptors. Pre-αβ T-cells undergo TCR-β rearrangement, a 
maturation process that involves active signaling with a collection of proteins. The active 
signaling prevents the maturation of pre-αβ T-cells that contain mutations in key T-cell proteins 
and allow normal pre-αβ T-cells to mature (Harraway, 2013).  
Once emerging from β-selection, the T-cells undergo 6-8 cell divisions and TCR α-locus 
recombination forming mature αβ TCRs.  The mature thymocytes also begin to express CD8 and 
CD4 receptor proteins on their respective cells making them double-positive (DP) T-cells (i.e. 
TCR+/ CD4+) (Germain, 2002).  
 
T-Cell Selection 
Approximately 90% of DP T-cells undergo apoptosis during the first stage of TCR 
signaling-mediated selection. Cell death is driven by the lack of TCR interaction with available 
peptide-MHC ligands expressed at the surface of APCs (Figure-4). Without adequate binding to 
peptide-MHC complexes, the cells do not produce essential intracellular signals required to 
sustain variability (Germain, 2002) resulting in cell death. The remaining 5-10% of the T-cells 
undergo additional selection processes referred to as positive and negative selection. Negative 
selection prevents TRCs that bind extremely well with MHC ligands from surviving, which 
could cause autoimmunity. TCRs that produce a balanced signal (not too weak and not too 
strong) between MHC ligands begin a single positive (SP) lineage divergence referred to as 
positive selection.  
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Figure-4:  Diagram of T-Cell Selection.  Shown are the Instruction 
Model (left side) and Stochastic Model (right side) of double-positive T-
cell lineage divergences. (Germain, 2002) 
 
Role of MHC I and II in T-Cell Selection 
Lineage divergence of double-positive thymocytes (i.e. TCR+/CD4+) is mediated by 
MHC class I and class II complexes.  The major histocompatibity complex (MHC) is a 
heterodimeric glycoprotein that serves as APC surface receptor that binds to TCRs (Zacharias et 
al., 2004). MHC molecules are subdivided into class I and class II surface molecules. Class-I 
MHC molecules present intracellular-derived antigen fragments to CD8+ T-cells, while class-II 
MHC molecules present exogenously-derived antigenic peptides to CD4+ T cells (Figure-4). 
Differentiation of DP T-cells to SP cells involves the silencing of transcription factors of either 
the CD4 or CD8 co-receptor locus. It is suggested that the silencing of one lineage locus is due to 
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affective signaling to either MHC class I or II molecules, or that the silencing occurs randomly, 
the latter is more supported (Figure-4).  
 
Autoimmunity and T-Cell Selection 
Cross-reactivity results from a failure of the T-cell negative selection process to eliminate 
self-peptides during T-cell maturation. During autoimmunity, self-peptides are recognized as 
foreign antigens, T-cells reactive against them are not eliminated, and they mount an attack 
against tissues expressing the self-antigen.  Because MHCs express the antigens in APC’s, they 
play a significant role in T-cell development and cross-reactivity. As previously discussed in the 
MS genetics section, some HLA alleles are associated with autoimmune disorders, including 
MS.  The strongest correlations are for the HLA-DR locus (Deluca et al., 2007).  The specific 
HLA-DR peptide sequence that triggers myelin-autoreactive T-cells in MS is unknown, and is 
the subject of this project. Variants in the HLA-DR β1 locus appear to be involved, but not HLA-
DRα (Deluca et al., 2007).   
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PROJECT PURPOSE 
 
 As stated in the Background section, activated CD4+ T-cells targeting specific auto-
antigenic peptides of myelin-sheath proteins are thought to mediate MS pathogenesis, but the 
mechanism remains unknown.  MS susceptibility maps to specific HLA-DRβ1 alleles whose 
products help present antigens to the immune system.  MS susceptibility increases with the 
expression of the HLA-DRβ1 locus. HLA-presented antigens at the surface of antigen presenting 
cells (APCs) are crucial for the development of T-cells and are also involved in T-cell auto-
reactivity.  
Current mouse EAE research models are limited in their usefulness. The current model 
uses an artificial induction of activated T-cells to induce inflammation, demyelination, axonal 
loss, and gliosis that mimic some aspects of MS, but it cannot account for the heterogeneous 
symptoms observed in MS patients, nor can the model accurately demonstrate how genetic 
factors (such as the HLA-DRβ1 alleles) and environmental factors activate CD4+ T-cells to 
generate an immune response at the BBB against self-antigens.  
In an effort to determine the combination of peptide / HLA-DRβ1 molecule(s) 
responsible for the auto-reactivity of myelin reactive T-cells, we constructed over 45 soluble 
HLA-DR β1 molecules presenting 18 different myelin peptides.  Two MHC variants HLA-DR 
β1 04.01, and HLA-DR β1 15.01 are known to increase the risk of autoimmune disorders such as 
MS (Barcellos et al, 2006; Deluca et al, 2007). These two MS MHC variants, and a control 
HLA-DR β1 01.01 (not know to increase the risk of MS) were constructed by recombinant DNA 
cloning, and combined with the genes encoding 18 different myelin peptides, and expressed at 
the surface of Sf-9 insect cells to determine the auto-antigenic capacity of each pMHC complex.  
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The myelin peptides tested were selected via MS patient mapping and the IEDB epitope 
prediction database (see Methods). Each peptide represents a 12-19 amino acid portion of full-
length proteins located at the surface of myelin sheaths. The three sheath proteins tested were 
myelin proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), and myelin basic 
protein (MBP). PLP is essential for the compaction of myelin sheaths and may help stabilize and 
maintain myelin (Nadon et al., 1998).  MBP is the most abundant protein on myelin sheaths, and 
is commonly used as a marker for the breakdown of sheaths (Deber and Reynolds, 1991).  The 
role of MBP is scarcely understood, but it may also interact with lipids to stabilize and maintain 
the correct structure of myelin. Myelin oligodendrocyte glycoprotein (MOG) has been found to 
have no phenotype when knocked-out in mice (Delarasse et al., 2003), so its normal function 
remains unknown.  But MOG T-cell activation appears to be important in EAE models 
(Delarasse et al., 2003). 
In order to identify the encephelo-antigenic properties of each MHC and peptide 
combination, transgenic HLA-DR β1 15.01 and HLA-DR β1 04.01 mice were challenged with 
the full-length peptides identical to the ones used to construct the pMHC soluble molecules. The 
challenged mice were then scored using the EAE scoring system to phenotypically identify 
whether the mice had EAE.  
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METHODS 
 
Synthetic Peptides and Oligonucleotides  
DNAs encoding various peptides to myelin sheath proteins were amplified by PCR from 
plasmids in our lab. The reverse-oligonucleotides used were developed using a combination of 
template overlapping region, peptide sequence, a linker, and one SpeI enzyme site, respectively. 
The oligonucleotides developed enabled us to PCR-in (clone the peptide-encoding sequence as 
part of the HLA PCR) each peptide sequence with corresponding HLA-DR β1 variants. The 
forward-oligonucleotides were designed previously in our lab, and primed the HLA-DR β1chain. 
18 peptides corresponding to different myelin sheath protein epitopes were designed (Table-1), 
and each were combined with the three HLA-DR β1 variants tested (01.01 (control), 04.01, and 
15.01).  
Myelin Peptides Amino Acid Sequences 
PLP 190-204 SKTSASIGSLCADARMY 
PLP 175-192  YIYFNTWTTCQSIAFPSK 
PLP 172-195 TWTTCQSIAFPSKTSA 
PLP 39-53 LTGTEKLIETYFSKN 
PLP 40-58 TGTEKLIETYFSKNYQDYE 
PLP 181-195 TTCQSIAFPSKTSAS 
PLP 91-110  YTTGAVRQIFGDYKTTICGK 
PLP 97-108  RQIFGDYKTTIC 
MOG 33-47 TGMEVGWYRSPFSRV 
MOG 38-51 VGWYRSPFSRVVHLY 
MOG 97-108  TCFFRDHSYQEE 
MOG 31-49 NATGMEVGWYRSPFSRVVH 
MOG 41-55 RPPFSRVVHLYRNGK 
MBP 85-100 ENPVVHFFKNIVTPRT 
MBP 30-44 PRHRDTGILDSIGRF 
MBP 85-99 ENPVVHFFKNITPR 
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MBP 131-145  ASDYKSAHKGFKGVD 
MBP 140-154  GFKGVDAQGTLSKIF 
 
Table-1: Amino Acid Sequences of Myelin Sheath Peptides. Shown 
are the 18 different peptide sequences chosen for testing in this project, 
and their corresponding amino acid sequence used to produce the various 
peptide-MHC combinations.  The three sheath proteins tested were 
myelin proteolipid protein (PLP), myelin oligodendrocyte glycoprotein 
(MOG), and myelin basic protein (MBP). 
 
The peptides used in the EAE injection experiments were synthesized at the University of 
Massachusetts Medical School. In order to minimize frameshifts in the pMHC constructs which 
would disrupt the TCR-binding region of the MHC complex, truncated versions of the peptides 
were used. Full-length peptides were utilized in the EAE induction experiments. 
 
Recombinant HLA-DRβ1 pBAC Plasmid Constructs 
HLA variant cDNA genes 01.01 (control), 04.01, and 15.01 were amplified by PCR from 
plasmids prepared in our lab. To display the pMHC combinations at the surface of baculovirus 
infected cells, modifications were made by flanking the HLA-DR β1variants with Acc651 and 
BsiWI restriction sites, and subcloning the fragments into pBAC vectors to enable the surface 
expression of the complex. The site encoding the HLA-DR β1 peptide-binding region was then 
disrupted by cutting with EcoRI and SpeI enzymes, and then ligated with similarly cut amplicons 
encoding various sheath peptides. This enabled the HLA-DR β1variants to express the 
previously designed peptides (Table-1) at the surface of the MHC molecules.  
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Plasmid DNA Isolation 
The pBAC vector constructs containing recombinant HLA-DR/peptide sequences were 
transformed into XL1-Blue E. coli (Stratagene, La Jolla, California, United States). Promega 
DNA purification kits were used to isolate and purify plasmid DNA from E. coli cultures.   
 
DNA Sequencing 
DNA sequencing was used to verify the nucleotide sequences of the cloned constructs 
and to ensure that no mutations, frameshifts, and/or other unwanted alterations had occurred 
during the DNA construction process. The HLA-DR β1 region with corresponding peptide-
encoding and transmembrane anchoring region were sequenced. pMHC pBAC construct was 
sequenced using Genewiz (Cambridge, MA), a contract research organization that specializes in 
DNA sequencing. Sequences were then analyzed using the pDRAW software (PDRAW. 
Sunnyvale, CA).   
 
Transfection of SF9 Cells  
The transfection protocol used was as previously outlined in Invitrogen expression 
protocols (ViraPowe BacMam Expression System and BacMam pCMV-DEST Vector Kit).  
1x106 Sf-9 cells were plated for each construct in supplemented Grace’s medium. The cells were 
allowed to incubate for 45 minutes at 27oC and then washed with unsupplemented Grace’s 
medium and plated on 0.8ml of unsupplemented Grace’s medium.  A mixture of 20ng of purified 
baculovirus DNA, 500ng of plasmid DNA, 4ul of Cellfectin, and 100ul of unsupplemented 
Grace’s medium was made and incubated for 45 minutes at room temperature. The mixture was 
then added to the Sf-9 cells and incubated at 27oC for 4 hours. After the incubation, the cells 
were washed once with unsupplemented Grace’s medium and plated on 3ml of Supplemented 
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Grace’s medium. Cells were then incubated at 27oC for 7 days, and viruses were harvested on 
day 14.  
 
mAbs and Flow Cytometry 
FACS analysis was used to assay the expression of various peptide/HLA-DR complexes 
on the surface of transfected SF9 cells.  Transfected Sf-9 cells expressing peptide/HLA-DRB1 
variants were harvested on day 7.  200ul of cells were collected from each Sf-9 transfection and 
spun down for 4 minutes at 1,400rpm. Cells were then stained with HLA-DR mAbs (Becton 
Dickinson Bioscience, Concord, MA) containing an allophycocyanin (APC) fluorophore to mark 
HLA-DR expression with the color blue. A balanced salt solution (BSS) buffer was then added 
to the stained cells and allowed to incubate at room temperature for 45 minutes. Once stained, 
cells were spun down for 4 minutes at 1,400rpm and washed with BSS, and once again spun 
down under the same conditions. After this wash, the stained cells were re-suspended in BSS 
wash buffer and analyzed by FACS using both a SORP and LSR machine.  
 
EAE Induction/EAE Mice Scoring 
In order to test the encephalo-antigenic nature of each peptide-MHC combination, NSG 
(NOD, SCID, IL2 common gamma chain deficient) mice with MHC II knockout and transgenic 
for either HLA-DRB1 15.01, or 04.01 were challenged with antigen/peptides previously 
described in Table-1. On day zero, NSG transgenic mice were injected subcutaneously with an 
emulsion consisting of a 4mg/ml concentration of complete Freud’s adjuvant (CFA) (Miller et 
al., 2007) combined with 533ug of mycobacterium tuberculosis peptide and 400ug of a specific 
antigen/peptide. This injection was then followed by an intraperitoneal (IP) injection of 200ng of 
pertussis toxin, and two days following the first immunization a second IP injection of 200ng of 
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pertussis toxin was given (Miller et al., 2007) (Figure-5). Following the injections, the mice 
were weighed and scored daily for 27 days after the first emulsion and IP injection were given. A 
classical EAE scoring system was adopted for the study to systemically determine EAE 
symptoms (Hooke Laboratories, Lawrence, Massachusetts, United States). Mice were scored on 
a scale from 0 to 5, with zero being normal and 5 being morbid. A score of zero equates no 
apparent paralysis, a score of one equates to paralysis of the tail or an apparent limp tail, a score 
of two indicates the mice had a limp tail and one paralyzed hind limb, a score of three is 
associated with a limp tail and two both paralyzed hind limbs. Scores four and five are the most 
severe; a score of four indicates that the mouse has a limp tail, two paralyzed hind limbs, and 
partial front leg paralysis, and finally a scored of five equates  to a mouse found completely 
paralyzed, or dead due to paralysis (Figure-5). Mice who appeared on the border of one score or 
another were scored with an additional 0.5 to indicate their possible transition to a higher score.  
 
Figure-5: Diagram of Injections for EAE Induction and Scoring 
Procedure. The figure illustrates the EAE induction process of NSG 
HLA-DR transgenic mice induced with WT peptide/antigen MOG 35-55. 
The classical EAE scoring scale used to identify the disease in mice is 
also shown. 
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RESULTS 
 
 
Current mouse EAE research models are limited in their representation of multiple 
sclerosis (MS) pathology. The current model uses an artificial induction of activated T-cells to 
induce inflammation, demyelination, axonal loss, and gliosis that mimic some aspects of MS, but 
it cannot account for the heterogeneous symptom presentation commonly seen in MS patients, 
nor can it accurately demonstrate how genetic factors (such as the HLA-DRβ1 alleles) and 
environmental factors activate CD4+ T-cells to generate an immune response at the BBB against 
self-antigens.  
 
Surface Expression Experiments 
In an effort to facilitate the development of a new model system, HLA-DRβ1 alleles 
04.01 and 15.01 that correlate with an increased risk of developing MS were combined with 18 
different peptide epitopes of three proteins found within myelin sheaths. Recombinant MHC 
variants HLA-DRβ1 15.01 and 04.01 were modified as described in the Methods to anchor the 
molecule on the surface of insect cells. The variant MHC genes were then combined with DNAs 
encoding 18 different myelin protein epitopes and sequenced for accuracy (Methods, Table-1). 
The MHC variant HLA-DRβ1 01.01 not associated with MS or any other autoimmune disorder 
was also constructed and combined with the same antigen/epitopes as a negative control.  The 
diverse combinations of peptide/MHCs were developed to mimic the MHC restriction concept 
(Figure-6) which states that T-cell receptors must recognize (match) the specific MHC and 
peptide combination, to enable CD4+ T-cells to be specified for that specific MHC/peptide 
combination. Developing different peptide/MHC combinations not only allows the potential 
identification of specific antigens related to the initiation of MS, but also verification of which 
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component most likely increases the risk of MS (the peptide sequence or the MHC variant), and 
why the specific variant or peptide by-passes the negative selection process during T-cell 
development.  
 
 
  
Figure-6: Diagram of the MHC Restriction Concept. The left panel 
illustrates how the T-cell receptor (TCR) (blue) recognizes specific MHC 
(yellow) and ligand peptide (brown) combinations on an antigen 
presenting cell (light yellow). If the MHC does not match the TCR 
specificity (diagram center) there is no recognition/binding of the ligand 
complex. Similarly, if the peptide ligand does not match the TCR 
specificity (diagram right) the T-cell will not recognize the peptide/MHC 
complex.  (Janeway et al., 2008) 
 
Recombinant HLA-DRβ1 gene variants and their combined myelin protein gene epitopes 
were cloned into an expression plasmid, and expressed at the surface of Sf-9 insect cells as 
described in Methods. The expression levels of the HLA-DR molecules were analyzed by FACS 
using HLA-DR mAbs with an APC fluorophore (Figure-7). The hypothesis tested was that MS-
associated variants HLA-DRβ1 15.01 and 04.01 would have higher levels of expression than 
 25 
control variant HLA-DRβ1 01.01. However, the data showed no statistical difference between 
the various types of HLA-DR expression levels.  All peptide-MHC combinations (red curves) 
showed increased surface expression relative to the antibody omission non-expression control 
(blue curves).  Differences were observed for specific peptide/MHC combinations, which could 
affect differences in T-cell binding.  The highest level of expression was observed for HLA-
DRB1 15.01 combined with peptide MOG 33-47.  
 
 
Figure-7: FACs Analysis of the Sf-9 Cell Surface Expression of Various Peptide 
and HLA-DRβ1 Complexes.  HLA variants tested were 01.01 (control), and 04.01 and 
15.01 (MS-associated).  The peptides that were combined with the HLA variants are 
listed on the left side of the figure. Blue represents antibody omission negative controls, 
and red the HLA-specific antibody staining. 
 
MOG 33-47 
MBP 30-44 
PLP 39-53 
PLP 175-192 
HLA-DRβ1 15.01 HLA-DRβ1 01.01  HLA-DRβ1 04.01 
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These surface expression findings have relevance to the mechanisms previously 
discussed in the Background stating that surface expression levels are important for inducing T-
cell activation.  The T-cell must recognize the MHC-expressed self-antigen. Because all the 
peptide-HLA combinations showed some surface expression, a lack of expression likely is not 
responsible for inactivity in vivo.  In the future, T-cell binding assays could be conducted to 
determine whether the highest surface expressed combination (15.01 with MOG 33-47) is the 
most antigenic.  In vivo studies are also crucial to perform because of the wide variety of signals 
that affect CD4+ cell maturation and migration.   
The peptide/MHC combinations shown on Figure-7 are of peptides shown to develop 
classical EAE symptoms in our in vivo study, and that showed atypical symptoms or MS like 
symptoms. The peptides MOG 33-47 and PLP 175-192 are truncated versions of MOG 25-55 
and PLP 174-206 respectively. Truncated versions of these peptides were used to develop 
peptide/MHC constructs to prevent frameshifts at the peptide binding site of the MHC molecule 
that would in effect disrupt proper TRC ligand binding and recognition.   
 
 
Peptide Injection Experiments 
In order to assay the encephalo-antigenic properties of various HLA-DRβ1 15.01 and 
04.01 and myelin sheath peptides, NSG mice (lacking murine HLAs) transgenic for human 
HLA-DRβ1 15.01 or HLA-DRβ1 04.01 were injected with elongated versions of the peptides 
tested in the previous figure.  These in vivo studies enabled us to test which specific 
peptide/MHC combination might induce MS-like symptoms or EAE in mice expressing human 
MHC 15.01 or 04.01 molecules. The injected mice were weighed and scored daily as indicated in 
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the Methods Figure-5. The injected mice were scored for classic classical EAE symptoms such 
as progressive paralysis.   
Interestingly, HLA-DRβ1 variant 04.01 transgenic mice (thought to correlate with MS 
patients) did not develop any EAE or MS symptoms when challenged with any of the myelin 
peptides (data not shown). The 04.01 mice gained weight normally throughout the 27 day 
scoring period, further suggesting that variant 04.01 and the myelin peptides did not activate 
CD4+ T-cells against myelin proteins at the BBB.   
Variant HLA-DRβ1 15.01 transgenic mice showed classic EAE symptoms in mice 
challenged with peptides MOG 25-55 and MBP 30-44 (Figure-8, top two panels). One of 7 
15.01 mice challenged with MOG 25-55 showed a classical EAE score of 1.0 or 1.5 in days 10-
27 post-injection (Figure-8, top left panel). In this case, the EAE score of 1.0 was determined 
through the apparent tail paralysis of the mouse, and a score of 1.5 was given when the mouse 
appeared to have weakening of one hind limb (that eventually relapsed three days later). 
However, the reaction was not consistent, and the other seven 15.01 mice challenged with MOG 
25-55 did not develop classical EAE symptoms. One 15.01 mouse (B950) challenged with MBP 
30-44 developed a severe case of EAE on day 15 resulting in death (Figure-8, top right panel). 
Mouse B950 did not progressively develop EAE, but the disease reached morbid levels over the 
course of 24 hours with a classical EAE score of 5.0.  This mouse suggests that peptide MBP 30-
44 in 15.01 mice is able to activate CD4+ T-cells to MBP protein epitopes and elicit an 
immunogenic response at the BBB. The death of the mouse is not believed to be due to the 
induction EAE toxins, but due to the activation of CD4+ T-cells against the MBP epitope 
because no other mice given MBP 30-44 elicited severe classical EAE symptoms (Figure-8, top 
right panel). Transgenic HLA-DRβ1 15.01 mice challenged with peptide/antigens PLP 39-53 
(lower left panel) and PLP 174-206 (lower right panel) did not elicit classical EAE symptoms, 
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but were found to have atypical EAE symptoms and symptoms resembling MS patient symptoms 
(Table 2).  
  
 
Figure-8: Classic EAE Scores for HLA-DRβ1 15.01 Transgenic Mice 
Injected with Different Myelin Sheath Peptides.  The peptide injected 
is shown in the upper center of each panel.  Y-axis represents the classic 
EAE score determined as described in the Methods. 
 
The obvious symptoms of HLA-DRβ1 15.01 transgenic mice injected with peptides 
MOG 25-55, MBP 30-44, PLP 174-206, or PLP 39-53 were recorded to identify patterns and 
symptoms otherwise ignored by the EAE scoring system (Table-2). Peptide MBP 30-44 was 
injected into two 15.01 mice (B950 and B952).  Both died, but 950 showed classical EAE 
symptoms prior to death on day-15, while 952 dies on day-17 with no apparent EAE symptoms. 
The lack of illness in the days prior to 952’s death suggests that the mouse may have become 
morbid from EAE symptoms and died before a score could be recorded.  950’s death also 
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occurred quickly, but an EAE score was obtained.  Two 15.01 mice (B955 and B964) injected 
with peptide MOG 25-55 also died, with 955 showing classical EAE symptoms prior to death. 
Mouse B955 had an apparent front limb paralysis on day 14, and died two days later with no 
apparent remission increased severity of symptoms (Table-2). Four 15.01 mice (B982, B981, 
B978, and B979) were injected with peptide PLP 174-206.  Two of the mice were found dead 
(B982 and 981), B978 had an enlarged intestine (perhaps due to constipation), and B979 had a 
large bladder (lack of urination).  These symptoms are not characteristic of EAE, but are 
symptoms commonly seen in MS patients. Finally, four 15.01 mice (B984, B983, B975, and 
B973) were injected with peptide PLP 39-53.  B984, B983, and B975 were found dead on day-
10, but B973 developed atypical EAE characterized by a lack of natural reflexes and balance 
which are indications of possible neuronal damage elicited by CD4+ T-cells. B973 had an 
atypical score of 3.0 on day 11, with improper limb movement and no front limb reflexes 
(Table-2).  
 
Table-2: Symptoms of Mice Injected with Various Myelin Peptides.  
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Thus, some of the symptoms observed are not characteristic of classical EAE, but 
coincide with symptoms commonly seen in MS patients. This suggests that the heterogeneity of 
the MS disease creates different MS subtypes, each activating specific sets of CD4+ T-cells 
against different peptide/MHC complexes and eliciting different symptoms. This heterogeneity 
theory has been proposed previously (Barcellos, 2006; Disanto et al., 2011), but the current EAE 
model limits researchers from investigating the genetic aspects of MS.  
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DISCUSSION 
 
 
 
 Multiple sclerosis (MS) is a complex auto-immune disease with no effective cure despite 
years of extensive research. Researchers often depend upon the experimental autoimmune 
encephalomyelitis (EAE) mouse models, however, they do not accurately incorporate the 
clinical, radiological, pathological, and genetic features of MS (Denic et al., 2011). In this 
project, our EAE induction experiments showed that multiple peptides were capable of inducing 
EAE, which suggests there is not a specific protein target, but multiple targets that can produce 
the same demyelination and neuronal damage. From the EAE induction experiment we showed 
that variant HLA-DRB1 15.01, which correlates with a higher risk of developing MS in humans 
(Weatherby et al., 2001), is also the more encephalo-antigenic of the two HLA alleles (15.01 and 
04.01) tested. The encephalo-antigenic nature of the 15.01 variant seems to correlate more with 
the induction of EAE than the specific myelin protein epitope presented by 15.01. This opens the 
question of why negative selection during T-cell development does not destroy these myelin self-
antigens, and how variant 15.01 may be contributing to the self-antigen’s survival or 
presentation.  
In 15.01 mice, peptide/antigens MOG 25-55 and MBP 30-44 were shown to induce 
classical EAE symptoms, while peptides PLP 39-53 and PLP 174-206 induced the development 
of atypical EAE and MS patient-like symptoms. These findings suggest that the EAE model may 
elicit different symptoms depending on which myelin antigen is presented, and suggest that the 
heterogeneous presentation of MS in patients may correlate with the presence of different 
antigen-HLAs. Nonetheless, in order to establish more definitive conclusions, the EAE induction 
experiment should be repeated several times.  
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Because the 15.01 allele appears to be more encephalo-antigenic, the data show that the 
EAE model (that uses an artificial induction of activated T-cells to cause inflammation, 
demyelination, axonal loss, and gliosis) is not appropriate for studying the genetic features of 
MS. The EAE model scoring system in particular does not fully represent the heterogeneous 
clinical syndromes observed in MS patients, and does not take into consideration other neuronal 
damage symptoms besides paralysis. As indicated by our PLP peptide/antigen EAE induction 
experiments, symptoms much more related to MS than paralysis can be observed in these mice, 
but can go un-classified if using the EAE scoring system to characterize disease.  
In the future, in an effort to produce a genetically based MS animal model, recombinant 
HLA-DRβ1 constructs (with their corresponding peptides) used in our transfection experiments 
will be used to make tetramers. These tetramers will be used to challenge/activate MS patient T-
cells, which we hope will identify patient-specific peptide-MHC combinations responsible for 
the pathogenesis of MS. These constructs and patient T-cells studied will then be used to make a 
more genetically-driven MS animal model. 
 
 
 33 
BIBLIOGRAPHY 
 
Ascherio A, Munger KL (2007) "Environmental Risk Factors for Multiple Sclerosis. Part I: The 
Role of Infection".  Annals of Neurology, 61 (4): 288–299. 
 
Baranzini SE (2011) "Revealing the Genetic Basis of Multiple Sclerosis: Are We There Yet?” 
Current Opinion in Genetics & Development, 21 (3): 317–324. 
 
Barcellos LF (2006) "Heterogeneity at the HLA-DRB1 Locus and Risk for Multiple Sclerosis." 
Human Molecular Genetics, 15.18 (2006): 2813-2824. Web. 
 
Berer K, and Krishnamoorthy G (2014) "Microbial View of Central Nervous System 
Autoimmunity". FEBS Letters, 588(22): 4207–4213. 
 
Briggs FB, Goldstein BA, Mccauley JL, Zuvich RL, De Jager PL, Rioux JD, Ivinson AJ, 
Compston A, Hafler DA, Hauser SL, Oksenberg JR, Sawcer SJ, Pericak-Vance MA, Haines JL, 
and Barcellos LF (2010) "Variation within DNA Repair Pathway Genes and Risk of Multiple 
Sclerosis." American Journal of Epidemiology, 172.2 (2010): 217-224. Web.  
 
Chari DM (2007) "Remyelination in Multiple Sclerosis". International Review of Neurobiology, 
79: 589–620. 
 
Comabella M, Craig DW, Camiña-Tato M, Morcillo C, Lopez C, Navarro A, Rio J, Montalban 
X, and Martin R (2008) "Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 
by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms." Ed. Katrina 
Gwinn. PLoS ONE, 3.10 (2008): E3490. Web.  
 
Compston A, Coles A (2008) "Multiple Sclerosis". Lancet, 372 (9648): 1502–1517. 
 
Constantinescu CS, Farooqi N, O'brien K, and Gran B (2011) "Experimental Autoimmune 
Encephalomyelitis (EAE) as a Model for Multiple Sclerosis (MS)." British Journal of 
Pharmacology, 164.4 (2011): 1079-1106. Web. 
 
Deber CM, Reynolds SJ (1991) "Central Nervous System Myelin: Structure, Function, and 
Pathology".  Clinical Biochemistry, 24 (2): 113–134. 
 
Delarasse C, Daubas P, Mars LT, Vizler C, Litzenburger T, Iglesias A, Bauer J, Della Gaspera B, 
Schubart A, Decker L, Dimitri D, Roussel G, Dierich A, Amor S, Dautigny A, Liblau R, Pham-
Dinh D (2003) “Myelin/oligodendrocyte Glycoprotein–deficient (MOG-Deficient) Mice Reveal 
Lack of Immune Tolerance to MOG in Wild-Type Mice.” Journal of Clinical Investigation, 
112.4 (2003): 544–553. PMC. Web.  
 
 
 
 
 34 
Deluca GC, Ramagopalan SV, Herrera BM, Dyment DA, Lincoln MR, Montpetit A, Pugliatti M, 
Barnardo MCN, Risch NJ, Sadovnick AD, Chao M, Sotgiu S, Hudson TJ, and Ebers GC (2007) 
"An Extremes of Outcome Strategy Provides Evidence That Multiple Sclerosis Severity Is 
Determined by Alleles at the HLA-DRB1 Locus." Proceedings of the National Academy of 
Sciences, 104.52 (2007): 20896-20901. Web. 
 
Denic, Aleksandar et al. (2011) “The Relevance of Animal Models in Multiple Sclerosis 
Research.” Pathophysiology : the official journal of the International Society for 
Pathophysiology / ISP 18.1 (2011): 10.1016/j.pathophys.2010.04.004. PMC. Web.  
 
Disanto, Giulio, Antonio J. Berlanga, Adam E. Handel, Andrea E. Para, Amy M. Burrell, 
Anastasia Fries, Lahiru Handunnetthi, Gabriele C. De Luca, and Julia M. Morahan. 
"Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex 
Disease." Autoimmune Diseases 2011 (2011): 1-12. Web. 
 
Dyment DA, Ebers GC, Sadovnick AD (2004) "Genetics of Multiple Sclerosis". Lancet 
Neurology, 3 (92): 104–110. 
 
Germain RN (2002) "T-cell Development and the CD4–CD8 Lineage Decision." Nature Reviews 
Immunology, 2(5): 309-322. Web.  
 
Global Burden of Disease Study (2014) "Global, regional, and national age-sex specific all-cause 
and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the 
Global Burden of Disease Study."  Lancet, 385: 117–171. 
 
Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, and Hunninghake GW (2008) 
"Respiratory Epithelial Cells Convert Inactive Vitamin D to its Active Form: Potential Effects on 
Host Defense." Journal of Immunology, 7090-7099 181.10 (2008): n. page. Web. 
 
Harraway J (2013) "T & B Cell Gene Rearrangement Assays an Introduction." Sullivan 
Nicolaides Pathology, 09909 (2013): n. page. Web. 
 
Hassan-Smith G, Douglas MR (2011) "Epidemiology and diagnosis of multiple sclerosis." 
British Journal of Hospital Medicine, 72 (10): M146–151. 
 
Janeway CA, Murphy KP, Travers P, and Walport M (2008) Janeway's Immunobiology. New 
York, NY: Garland Science, 2008. Print. 
 
Lublin FD, and Reingold SC (1996) "Defining the Clinical Course of Multiple Sclerosis: Results 
of an International Survey". Neurology, 46 (4): 907–911. 
 
Mcfarland HF, and Martin R (2007) "Multiple Sclerosis: A Complicated Picture of 
Autoimmunity." Nature Immunology, 8.9 (2007): 913-919. Web. 
 
Mehra, Narinder K., and Gurvinder Kaur. "Gene Map of the Human Leukocyte Antigen (HLA) 
Region." Cambridge University Press 5.24 (2003): n. page.  
 
 35 
Miller, Stephen D., William J. Karpus, and Todd Scott Davidson. "Experimental Autoimmune 
Encephalomyelitis in the Mouse." Current Protocols in Immunology (2007): no page. Print. 
 
Milo R, and Kahana E (2010) "Multiple Sclerosis: Geoepidemiology, Genetics and the 
Environment".  Autoimmunity Reviews, 9 (5): A387–394. 
 
Nadon NL, and West M (1998) "Myelin Proteolipid Protein: Function in Myelin Structure Is 
Distinct from Its Role in Oligodendrocyte Development." Developmental Neuroscience, 20.6 
(1998): 533-539. Web. 
 
National Multiple Sclerosis Society (NMSS). National Multiple Sclerosis Society (NMSS). Print. 
 
PDRAW. Sunnyvale, CA: PC Software Interest Group, 1984. Computer software. 
 
Pereira, B De Andrade, M. Ackermann, S. Chaudhary, R. Vogel, B. Vogt, and C. Fraefel. 
"Tolerance of Activated Pathogenic CD4+ T Cells by Transcriptional Targeting of Dendritic 
Cells." Nature Gene Therapy, 1476-5462 22.0969-7128 (2015): n. page. Web.   
 
Ramagopalan SV, Lee JD, Yee IM, Guimond C, Traboulsee AL, Ebers GC, and Sadovnick AD 
(2013) "Association of Smoking with Risk of Multiple Sclerosis: A Population-based Study." 
Journal of Neurology, 260.7 (2013): 1778-1781. Web. 
 
Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi 
P, Salvetti M, Faggioni A, and Aloisi F. "Dysregulated Epstein-Barr Virus Infection in the 
Multiple Sclerosis Brain." Journal of Experimental Medicine, 204.12 (2007): 2899-2912. Web. 
 
Weatherby SJM, Thomson W, Pepper L, Donn R, Worthington J, Mann CLA, Davies MB, Fryer 
AA, Boggild MD, Young CA, Jones PW, Strange RC, Ollier WER, and Hawkins CP (2001) 
"HLA-DRB1 and Disease Outcome in Multiple Sclerosis." Journal of Neurology, 248.4 (2001): 
304-310. Web. 
 
Zacharias M, and Spinger S (2004) "Conformational Flexibility of the MHC Class I Alpha1-
alpha2 Domain in Peptide Bound and Free States: A Molecular Dynamics Simulation Study." 
Biophysical Journal, 2203-2214, 87.4 (2004): n. page. Web. 
 
 
 
